PT Indofarma Tbk (ISX:INAF) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


ISX:INAF PT Indofarma Tbk ISX:INAF
8 GF Score
Price Rp126.00
GF Value Rp176.99
! 6 Warning Signs
View Full Analysis

What is PT Indofarma Tbk Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

PT Indofarma Tbk's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ISX:INAF vs ZTS, VTRS, NBIX: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PT Indofarma Tbk Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where PT Indofarma Tbk's Margin of Safety % (DCF FCF Based) falls into.


ISX:INAF
8GF Score
PT Indofarma Tbk ISX:INAF
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued. The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.

Key valuation signals for ISX:INAF:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
  • GF Score™: 8/100 with 6 warning signs

No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Indofarma Tbk Business Description

Address Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score

Get the complete analysis for ISX:INAF

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp126.00
Price
Rp176.99
GF Value